A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Inclusion Criteria: * Healthy male or female subjects between 18 and 65 years of age and body mass index (BMI) within the range 18.5 to 29.0 kilogram/meter squared. * Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and bilirubin \< or =1.5x upper limit of normal (ULN). * Female subjects of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy during the study. * Average QT duration corrected for heart rate by Fridericia's formula (QTcF) \<450 millisecond. * Forced Expiratory Volume in 1 Second (FEV1) \> or = 85% predicted at screening. * Current non-smokers * Able to satisfactorily use the NDPI. Exclusion Criteria: * Subjects must not have a systolic blood pressure above 145 milimeter(mm) of mercury(Hg) or a diastolic pressure above 85 mmHg at the screening visit. * History of breathing problems in adult life confirmed by normal lung function parameters (≥85% predicted). * Donation of more than 500 mL blood within a 56 day period. * Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit. * Current or chronic history of liver disease, or known hepatic or biliary abnormalities. * The subject treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness. * The subject has a positive: drug/alcohol, Hepatitis, HIV screen. * Abuse of alcohol. * Subject having positive cotinine and urine alcohol test. * Participated in \>3 clinical trials in the previous 10 months (if male), or \>2 clinical trials in the previous 10 months (if female), or the subject has participated in a study (including follow up) within 60 days prior to the first dosing day in the current study. * Exposure to more than four new chemical entities within 12 months prior to the first dosing day. * Taken systemic, oral or depot corticosteroids less than 12 weeks or inhaled, intranasal or topical steroids less than 4 weeks before the screening visit. * Use of prescription or non-prescription drugs. * History of severe milk protein allergy, sensitivity to any of the study medications, including immediate or delayed hypersensitivity to any intranasal, inhaled or systemic corticosteroid therapy. * Pregnant or lactating females. * Unwillingness or inability to follow the procedures outlined in the protocol. * Subject is mentally or legally incapacitated.